Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors

Journal of Medicinal Chemistry

Volumn 43, Issue 2, 2000, Pages 156-166

  O'Brien, Patrick M ^a   Ortwine, Daniel F ^a   Pavlovsky, Alexander G ^a   Picard, Joseph A ^a   Sliskovic, Drago R ^a   Roth, Bruce D ^a   Dyer, Richard D ^a   Johnson, Linda L ^a   Man, Chiu Fai ^a   Hallak, Hussein ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4' BROMOBIPHENYL 4 SULFONYLAMINO) N HYDROXY 3 METHYLBUTYRAMIDE; CIPEMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; TANOMASTAT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOMER; NONHUMAN; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CRYSTALLOGRAPHY, X-RAY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MATRIX METALLOPROTEINASES; MODELS, MOLECULAR; PROTEASE INHIBITORS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0034719482     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9903141     Document Type: Article

References (34)

1. Matrisian, L. M. The Matrix Degrading Proteinases. Bioessays 1992, 14, 455-463.
2. Denhardt, D. T.; Feng, B.; Edwards, D. R.; Cocuzzi, E. T.; Malyankar, U. M. Tissue Inhibitor of Metalloproteinases (TIMP, aka EPA): Structure, Control of Expression and Biological Function. Pharmacol. Ther. 1993, 59, 329-341.
3. Firestein, G. S.; Paine, M. M.; Littman, B. H. Gene Expression (Collagenase, Tissue Inhibitors of Metalloproteinase, Complement and HLA-DR) in Rheumatoid and Osteoarthritic Synovium. Arthritis Rheum. 1991, 34, 1094-1105.
4. Pyke, C.; Ralfkiaer, E.; Huhtala, P.; Hurskainen, T.; Danoe, K.; Tryggvason, K. Localization of Messenger RNA for Mr 72,000 and 92,000 Type IV Collagenases in Human Skin Cancers by in situ Hybridization. Cancer Res. 1992, 52, 1336-1341.
5. Thompson, R.; Parks, W. Role of Matrix Metalloproteinases in Abdominal Aortic Aneurysms. Ann. NY Acad. Sci. 1996, 800, 157-174.
6. Thomas, C. V.; Coker, M. L.; Zellner, J. L.; Handy, J. R.; Crumbly, A. J.; Spinale, F. G. Increased Matrix Metalloproteinase Activity and Selective Upregulation in LV Myocardium from Patients with End-Stage Dilated Cardiomyopathy. Circulation 1998, 97, 1708-1715.
7. Nagase, H. Matrix Metalloproteinases. In Zinc Metalloproteinases in Health and Disease; Hooper, N. M., Eds.; Taylor and Francis: London, 1996; pp 153-204.
8. (a) Nagase, H. Activation Mechanisms of Matrix Metalloproteinases. Biol. Chem. 1997, 378, 151-160.
9. (b) Massova, I.; Kotra, L. P.; Fridman, R.; Mobashery, S. Matrix Metalloproteinases: Structures, Evolution, and Diversification. FASEB 1998, 12, 1075-1095.
10. (a) Babine, E. R.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Application to Drug Design. Chem. Rev. 1997, 97, 1359-1472.
11. (b) Shuker, S.; Hajduk, P.; Meadows, R.; Fesik, S. Discovering High Affinity Ligands for Proteins: SAR by NMR. Science 1996, 274, 1531-1534.
12. Beckett, R. P.; Whittaker, M. Matrix Metalloproteinase Inhibitors 1998. Exp. Opin. Ther. Patents 1998, 8, 259-282.
13. Whittaker, M.; Brown, P. Recent Advances in Matrix Metalloproteinase Inhibitor Research and Development. Curr. Opin. Drug Discuss. 1998, 1, 157-164.
14. Tamura, Y.; Watanabe, F.; Nakatani, T.; Yasui, K.; Fuji, M.; Komurasaki, T.; Tsuzuki, H.; Maekawa, R.; Yoshioka, T.; Kawada, K.; Sugita, K.; Ohtani, M. Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2): N-Sulfonylamino Acid Derivatives. J. Med. Chem. 1998, 41, 640-649.
15. Pavlovsky, A.; Ye, Q. Z.; Ortwine, D.; Humblet, C.; Purchase, C.; White, A.; Roth, B.; Johnson, L.; Hupe, D.; Williams, M.; Dhanaraj, V.; Blundell, T. X-ray Structure of Human Stromelysin Catalytic Domain Complexed with Non-Peptide Inhibitors: Implications for Inhibitor Selectivity. Protein Sci. 1999, 8, 1455-1462. Entry 1ceaq in the Protein Databank.
16. Miyaura, N.; Yanagi, T.; Suzuki, A. The Palladium-Catalyzed Cross-Coupling Reaction of Phenylboronic Acid with Haloarenes in the Presence of Bases. Synth. Commun. 1981, 11, 513-519.
17. Wilhelm, S. M.; Shao, Z. H.; Housely, T. J.; Seperack, P. K.; Baumann, A. P.; Gunja-Smith, Z.; Woessner, J. F. Matrix Metalloproteinase-3 (Stromelysin-1). Identification as the Cartilage Acid Metalloprotease and Effect of pH on Catalytic Properties and Calcium Affinity. J. Biol. Chem. 1993, 268, 21906-21913.
18. Holman, C.; Kan, C. C.; Gehring, M.; Van Wart, H. Role of His-224 in the Anomolous pH Dependence of Human Stromelysin-1. Biochemistry 1999, 38, 677-681.
19. Johnson, L. L.; Pavlovsky, A. G.; Johnson, A. R.; Hupe, D. J.; Janowicz, J. A.; Man, C.-F.; Ortwine, D. F.; Purchase, C. F., III; White, A. D. A Rationalization of the Acidic pH Dependence for Stromelysin-1 (MMP-3) Catalysis and Inhibition. J. Biol. Chem., submitted.
20. Johnson, L.; Bornemeier, D.; Janowicz, J.; Chen, J.; Pavlovsky, A.; Ortwine, D. Effect of Species Differences on Stromelysin-1 (MMP-3) Inhibitor Potency: An Explanation of Inhibitor Selectivity Using Homology Modeling and Chimeric Proteins. J. Biol. Chem. 1999, 274, 24881-24887.
21. Parker, M. H.; Lunney, E. A.; Ortwine, D. F.; Pavlovsky, A. G.; Humblet, C.; Brouillette, C. G. Analysis of the Binding of Hydroxamic Acid and Carboxylic Acid Inhibitors to the Stromelysin-1 (Matrix Metalloproteinase-3) Catalytic Domain by Isothermal Titration Calorimetry. Biochemistry 1999, 38, 13592-13601.
22. Dhanaraj, V.; Ye, Qui-Zhuang; Johnson, L. L.; Hupe, D. J.; Ortwine, D. F.; Dunbar, J. B., Jr; Rubin, J. R.; Pavlovsky, A.; Humblet, C.; Blundell, T. L. X-ray Structure of a Hydroxamate Inhibitor Complex of Stromelysin Catalytic Domain and its Comparison with Members of the Zinc Metalloproteinase Superfamily. Structure 1996, 4, 375-386.
23. Massova, I.; Fridman, R.; Mobashery, S. Structural Insights into the Catalytic Domains of Human Matrix Metalloprotease-2 and Human Matrix Metalloprotease-9: Implications for Substrate Specificities. J. Mol. Model. [Electronic Publication] 1997, 3, 17-30.
24. Lovejoy, B.; Welch, A. R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R. T.; Campbell, J. A.; Walker, K.; Martin, R.; Van Wart, H.; Browner, M. Crystal Structures of MMP-1 and MMP-13 Reveal the Structural Basis for Selectivity of Collagenase Inhibitors. Struct. Biol. 1999, 6, 217-221.
25. Ye, Q. Z.; Johnson, L.; Hupe, D. J.; Baragi, V. Purification and Characterization of the Human Sromelysin Catalytic Domain Expressed in Escherichia coli. Biochemistry 1992, 31, 11231-11235.
26. Harrison, R. K.; Chang, B.; Niedzwiecki, L.; Stein, R. L. Mechanistic Studies on the Human Matrix Metalloproteinase Stromelysin. Biochemistry 1992, 31, 10757-10762.
27. Woessner, J. F.; Gunja-Smith, Z. Role of Metalloproteinases in Human Osteoarthritis. J. Rheumatol. 1991, 18, 99-101.
28. Commercially available from Tripos Associates, 1699 S. Hanley Rd, Suite 303, St. Louis, MO 63144-2913. Version 6.3, operating on Silicon Graphics workstations, was used for the calculations.
29. Commercially available from Wavefunction, Inc., 18401 Von Karman, Suite 370, Irvine, CA 92612. Version 5.1.1, operating on Silicon Graphics Octane, was used for the calculations.
30. The IMCA-CAT facilities are supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Illinois Institute of Technology (ITT), executed through the ITT's Center for Synchrotron Radiation Research and Instrumentation. Use of the Advanced Photon Source was supported by the U.S. Department of Energy, Basic Energy Sciences, Office of Energy Research, under Contract No. W-31-109-Eng-38.
31. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 1997, 276 (Macromolecular Crystallography, Part A), 307-326.
32. Navaza, J. AmoRe: An Automated Package for Molecular Replacement. Acta Crystallogr. 1994, A50, 157-163.
33. (a) Brunger, A. T.; Kuryan, J.; Karplus, M. Crystallographic R-Factor Refinement by Molecular Dynamics. Science 1987, 235, 458-460.
34. (b) Brunger, A. T. X-PLOR: A System for X-ray Crystallography and NMR; Yale University Press: New Haven, CT, 1992.